沉寂多时的CRO行业，新一轮行情蓄势待发！

Core Viewpoint - The clinical CRO sector is experiencing a significant recovery driven by the resurgence of innovative drug development, with a positive outlook for the industry as demand and supply dynamics improve [5][6][33]. Group 1: Demand Recovery - The demand for clinical CRO services is primarily driven by the R&D investments of innovative drug companies, with financing in the domestic innovative drug sector reaching $14.684 billion in 2025, a substantial increase of 127% year-on-year [9]. - Innovative drug business development (BD) transactions reached a record high in 2025, totaling $138.8 billion, which not only supports existing R&D pipelines but also lays the foundation for new projects, thereby boosting demand for clinical research [13]. - The number of clinical IND approvals in China is projected to reach 2,703 in 2025, marking a 19% increase year-on-year, with early-stage clinical trials showing particularly strong growth [15]. Group 2: Supply Side Optimization - The clinical CRO industry has seen a significant reduction in the number of companies, with a cumulative decline of 69% since 2021, leading to a more concentrated market dominated by leading firms [21]. - Major players like Tigermed have expanded their workforce during the industry downturn, enhancing their competitive edge through extensive project experience and client resources [24]. - In 2025, the number of ongoing clinical trials reached 20,602, with only 480 participating CROs, indicating an average of 42.9 trials per company, reflecting an increase of 20.6% from 2024 [27]. Group 3: Performance Improvement - The clinical CRO industry is entering a phase of simultaneous volume and price increases, with leading firms like Tigermed seeing a recovery in new order prices after a decline in 2023 and 2024 [29]. - In 2025, Tigermed is expected to secure new orders worth $9.5 to $10.5 billion, representing a year-on-year growth of 13% to 24%, while other leading firms also report significant increases in new and existing orders [31]. - The industry is witnessing a stabilization in revenue, with major firms showing growth in quarterly revenues since Q3 2025, supported by improved order prices and ongoing cost efficiency initiatives [32].